NCT06191848View on ClinicalTrials.gov

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

PHASE4RecruitingINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2037

Conditions
ObesityKnee OsteoarthritisOsteoarthritis, Knee
Interventions
DRUG

Tirzepatide

Participants will receive tirzepatide subcutaneously

DRUG

Placebo

Participants will receive placebo subcutaneously

Trial Locations (4)

3011

RECRUITING

Western Health, Melbourne

3065

RECRUITING

St Vincents Hospital Melbourne, Fitzroy

3084

RECRUITING

Austin Health-Repatriation Hospital, Melbourne

3128

RECRUITING

Eastern Health, Melbourne

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Melbourne

OTHER